Compare GSK plc (GSK) vs Microchip Technology Inc. (MCHP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Microchip Technology Inc. — how do they compare? GSK plc trades at $52.54 (market cap $101.34B), while Microchip Technology Inc. trades at $83.68 (market cap $46.84B). The key difference: GSK plc is far larger — about 2.2× Microchip Technology Inc.'s market cap, and GSK plc pays the higher dividend (3.49%). Which is the better fit depends on your goals.
| GSK | MCHP | |
|---|---|---|
Market Cap | $101.34B | $46.84B |
Sector | Health | Technology |
52-Week High | $61.18 | $102.97 |
52-Week Low | $36.20 | $49.02 |
Enterprise Value | $121.95B | $52.13B |
Dividend Yield | 3.49% | 2.11% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK's stock trades at $51.25, down 1.99% on the day, with a bearish technical signal from moving averages. Fundamentally, the company shows strong profitability with a 17.78% net margin and 36.42% ROE, supported by a consistent earnings beat history. Recent positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline progress. Valuation appears reasonable with a P/E of 13.71 and EV/EBITDA of 9.16.
The outlook balances a solid core business and promising oncology pipeline against a mixed analyst consensus and near-term cash flow pressures. Key opportunities lie in execution of new drug launches and the upcoming CEO strategy update, while risks include clinical trial setbacks, competitive pressures, and integration of potential acquisitions like Nuvalent.
MCHP trades at $87.11, up 3.42% today, with a neutral technical signal and bullish moving averages. The stock has beaten EPS estimates for three consecutive quarters, though 2025 saw a net loss. Analyst consensus is strongly bullish with a $113.33 price target, supported by positive news on AI, industrial IoT, and aerospace demand.
The outlook is positive given strong analyst support and exposure to growth markets, but high valuation ratios and recent profitability pressures pose risks. Upside depends on continued earnings beats and sector recovery, while debt levels and margin volatility require monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Microchip Technology Inc.
Microchip became an independent company in 1989 when it was spun off from General Instrument. More than half of revenue comes from MCUs, which are used in a wide array of electronic devices from remote controls to garage door openers to power windows in autos. The company's strength lies in lower-end 8-bit MCUs that are suitable for a wider range of less technologically advanced devices, but the firm has expanded its presence in higher-end MCUs and analog chips as well.
Read more on MCHP →
